Some stem cell lines are more equal than others
This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts.
Scientists have long complained that the Bush administration’s stem cell funding policy restricted their research to only a handful of human embryonic stem cell lines. That was an understatement, according to a study published today in Nature Biotechnology.
Researchers from Stanford University, the Mayo Clinic and the University of Michigan analyzed all 1,217 requests for stem cell lines that were made to the National Stem Cell Bank between 1999 and 2008. What they found was “far less diversity of materials than most believe,” they wrote.
Though the Bush administration said the bank maintained 21 cell lines eligible for funding from the National Institutes of Health, three of those lines have never been available to researchers, and a fourth line just became usable this year, the researchers said.
More than three-quarters of all requests involved just two of the remaining 17 cell lines. The H1 line accounted for 39% of the requests, and the H9 line made up another 38%, according to records from the stem cell bank. The only other line that has been requested more than 100 times is H7. Nine of the lines haven’t even made it into the double-digits.
The researchers also examined requests for human embryonic stem cell lines developed and maintained by the Harvard Stem Cell Institute. Harvard offers 28 cell lines, though the researchers focused on the 17 that have been available since 2004. (The others were too new to have been requested very much, they reasoned.) None of the Harvard lines could be used in NIH-funded experiments until the Obama administration’s more expansive funding policy took effect last month.
There was considerably more diversity in Harvard’s 946 shipments, according to the study. The two most popular cell lines accounted for only 25% of requests.
The researchers also scanned 534 stem cell studies published in peer-reviewed journals between 1999 and 2008. The H9 cell line appeared in 83% of studies, while the H1 line was in 61% and H7 was in 24%. Less than 36% of the publications included any of the other NIH lines.
The Harvard lines showed up in fewer than 3% of the studies published to date, according to the analysis.
The researchers speculated that scientists using federal funds might have been more conservative about their experiments and thus tended to cluster around the most popular NIH-approved lines. The pattern might also reflect a “first-mover advantage,” because laboratories seeking to replicate previous experiments probably used many of the same materials.
“The lasting legacy of Bush era policies,” the researchers concluded, is a human embryonic stem cell field “that relies very heavily on a small number of well-used but less than idea cell lines.”
-- Karen Kaplan